Evidence map›Paper›PMID 29725429›Full record

ArticleOncology letters2018

Effects of glabridin combined with 5-fluorouracil on the proliferation and apoptosis of gastric cancer cells.

Lei Zhang, Hongmei Chen, Mingfei Wang, Xiaojing Song, Fanghui Ding, Jun Zhu, Xun Li

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review on the Diverse Biological Effects of Glabridin.Drug design, development and therapy · 2023
    Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Lei ZhangFifth General Surgery Department, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China.
Hongmei ChenDepartment of Physiology, School of Basic Medical Sciences, Lanzhou University, Lanzhou, Gansu 730000, P.R. China.
Mingfei WangFifth General Surgery Department, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China.
Xiaojing SongFifth General Surgery Department, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China.
Fanghui DingFifth General Surgery Department, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China.
Jun ZhuDepartment of Pathology, The First Hospital of Lanzhou University, Lanzhou University, Lanzhou, Gansu 730000, P.R. China.
Xun LiFifth General Surgery Department, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China.
Lanzhou University · CNFirst Hospital of Lanzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric cancer most commonly occurs in East Asia, and China accounts for more than half the of world's gastric cancer burden. Despite the efficacy of chemotherapy for patients, this treatment leads to significant patient inconvenience, toxicity and cost. The present study aimed to assess a non-toxic agent, glabridin, as a future chemotherapeutic approach for treating gastric cancer. Using cell proliferation, apoptosis, invasion, and colony formation assays, it was determined that glabridin alone, or in combination with 5-fluorouracil (5-FU), inhibited MKN-45 cell proliferation and invasion, and increased apoptosis. These effects were accompanied by downregulation of p16, E-cadherin and apoptosis regulator Bcl-2 protein, and upregulation of N-cadherin, apoptosis regulator BAX and caspases 3, 8 and 9. The results demonstrated that glabridin may inhibit the malignant proliferation of the human gastric cancer MKN-45 cell line and enhance the efficiency of 5-FU. The data indicate that the p16, and potentially the p16/cyclin-dependent kinase 4/cyclin D1 pathway, may be a novel target for gastric cancer therapy.

Indexed as

5-FUapoptosisgastric cancerglabridininvasion

Identifiers

PMID29725429
PMCPMC5920351
OpenAlexW2790456193

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.